SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-15022"
 

Search: onr:"swepub:oai:DiVA.org:umu-15022" > Intensive treatment...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Simonsson, BengtUppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar (author)

Intensive treatment and stem cell transplantation in chronic myelogenous leukemia : long-term follow-up

  • Article/chapterEnglish2005

Publisher, publication year, extent ...

  • 2005-05-02
  • S. Karger AG,2005
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-15022
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-15022URI
  • https://doi.org/10.1159/000084445DOI
  • https://lup.lub.lu.se/record/896736URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-74465URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1955558URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-31892URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • In the present study we combined interferon (IFN) and hydroxyurea (HU) treatment, intensive chemotherapy and autologous stem cell transplantation (SCT) in newly diagnosed chronic myelogenous leukemia patients aged below 56 years, not eligible for allogeneic SCT. Patients who had an HLA-identical sibling donor and no contraindication went for an allogeneic SCT (related donor, RD). After diagnosis, patients not allotransplanted received HU and IFN to keep WBC and platelet counts low. After 6 months patients with Ph-positive cells still present in the bone marrow received 1–3 courses of intensive chemotherapy. Those who became Ph-negative after IFN + HU or after 1–3 chemotherapy courses underwent autologous SCT. Some patients with poor cytogenetic response were allotransplanted with an unrelated donor (URD). IFN + HU reduced the percentage of Ph-positive metaphases in 56% of patients, and 1 patient became Ph-negative. After one or two intensive cytotherapies 86 and 88% had a Ph reduction, and 34 and 40% became Ph-negative, respectively. In patients receiving a third intensive chemotherapy 92% achieved a Ph reduction and 8% became Ph-negative. The median survival after auto-SCT (n = 46) was 7.5 years. The chance of remaining Ph-negative for up to 10 years after autologous SCT was around 20%. The overall survival for allo-SCT RD (n = 91) and URD (n = 28) was almost the same, i.e. ≈60% at 10 years. The median survival for all 251 patients registered was 8 years (historical controls 3.5 years). The role of the treatment schedule presented in the imatinib era is discussed.

Subject headings and genre

  • MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Hematologi hsv//swe
  • MEDICAL AND HEALTH SCIENCES Clinical Medicine Hematology hsv//eng
  • Adolescent
  • Adult
  • Antineoplastic Agents/administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
  • Denmark
  • Female
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Hydroxyurea/administration & dosage
  • Interferons/administration & dosage
  • Leukapheresis
  • Leukemia; Myeloid; Philadelphia-Positive/mortality/*therapy
  • Male
  • Middle Aged
  • Multicenter Studies
  • Survival Analysis
  • Sweden
  • Transplantation; Autologous
  • Transplantation; Homologous
  • chronic myelogenous leukemia
  • chemotherapy
  • intensive
  • interferon
  • stem
  • cell transplantation
  • autologous and allogeneic
  • MEDICINE

Added entries (persons, corporate bodies, meetings, titles ...)

  • Öberg, GunnarUppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar (author)
  • Björeman, Mats (author)
  • Björkholm, MagnusKarolinska Institutet (author)
  • Carneskog, Jan (author)
  • Karlsson, KarinÖstergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Hematologiska kliniken US (author)
  • Gahrton, GöstaKarolinska Institutet (author)
  • Grimfors, Gunnar (author)
  • Hast, RobertKarolinska Institutet (author)
  • Karle, Hans (author)
  • Linder, Olle (author)
  • Ljungman, PerKarolinska Institutet (author)
  • Nielsen, Johan L (author)
  • Nilsson, Jonas (author)
  • Löfvenberg, EvaUppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi (author)
  • Malm, Claes,1945-Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Hematologiska kliniken US(Swepub:liu)clama59 (author)
  • Olsson, Karin (author)
  • Olsson-Strömberg, UllaUppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar (author)
  • Paul, ChristerKarolinska Institutet (author)
  • Stenke, LeifKarolinska Institutet (author)
  • Stentoft, Jesper (author)
  • Turesson, IngemarLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine(Swepub:lu)medf-itu (author)
  • Udén, Ann-Marie (author)
  • Wahlin, AndersUmeå universitet,Institutionen för folkhälsa och klinisk medicin(Swepub:umu)anwa0027 (author)
  • Vilén, Lars (author)
  • Weis-Bjerrum, Ole (author)
  • Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

  • In:Acta Haematologica: S. Karger AG113:3, s. 155-1620001-57921421-9662

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view